Shin Y, Lee J, Yoo J, Kim J, Jeon Y, Yoon Y
Eur Radiol. 2019; 29(9):4593-4602.
PMID: 30796567
DOI: 10.1007/s00330-018-5951-8.
Guo X, Fan C, Wang Y, Wang M, Cai C, Yang Y
Medicine (Baltimore). 2017; 96(11):e6249.
PMID: 28296734
PMC: 5369889.
DOI: 10.1097/MD.0000000000006249.
Refaat M, Fahed A, Hassanieh S, Hotait M, Arabi M, Skouri H
Card Electrophysiol Clin. 2016; 8(1):223-31.
PMID: 26920199
PMC: 6599619.
DOI: 10.1016/j.ccep.2015.10.034.
Achterberg H, Scheffer M, van Mechelen R, Kofflard M, Ten Cate F
Neth Heart J. 2015; 10(6):272-276.
PMID: 25696108
PMC: 2499779.
Rolf S, Haverkamp W
Herz. 2010; 34(7):528-38.
PMID: 20091252
DOI: 10.1007/s00059-009-3294-6.
Cardiac spectroscopy: techniques, indications and clinical results.
Beer M
Eur Radiol. 2004; 14(6):1034-47.
PMID: 15007617
DOI: 10.1007/s00330-004-2279-3.
Cardiac sympathetic nerve activity in patients with hypertrophic cardiomyopathy with malignant ventricular tachyarrhythmias.
Terai H, Shimizu M, Ino H, Yamaguchi M, Hayashi K, Sakata K
J Nucl Cardiol. 2003; 10(3):304-10.
PMID: 12794630
DOI: 10.1016/s1071-3581(03)00362-3.
Gap junction remodeling and altered connexin43 expression in the failing human heart.
Kostin S, Rieger M, Dammer S, Hein S, Richter M, Klovekorn W
Mol Cell Biochem. 2003; 242(1-2):135-44.
PMID: 12619876
Relation between QT duration and maximal wall thickness in familial hypertrophic cardiomyopathy.
Jouven X, Hagege A, Charron P, Carrier L, Dubourg O, Langlard J
Heart. 2002; 88(2):153-7.
PMID: 12117842
PMC: 1767224.
DOI: 10.1136/heart.88.2.153.
Clinical significance of atrial fibrillation in hypertrophic cardiomyopathy.
Olivotto I, Maron B, Cecchi F
Curr Cardiol Rep. 2001; 3(2):141-6.
PMID: 11177672
DOI: 10.1007/s11886-001-0041-x.
Hypertrophic Cardiomyopathy.
Barron
Curr Treat Options Cardiovasc Med. 2000; 1(3):277-282.
PMID: 11096493
DOI: 10.1007/s11936-999-0044-2.
Ventricular arrhythmias, sudden death, and prevention in patients with hypertrophic cardiomyopathy.
Maron B
Curr Cardiol Rep. 2000; 2(6):522-8.
PMID: 11060579
DOI: 10.1007/s11886-000-0037-y.
Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: assessment in an unselected non-referral based patient population.
Cecchi F, Olivotto I, Montereggi A, Squillatini G, Dolara A, Maron B
Heart. 1998; 79(4):331-6.
PMID: 9616338
PMC: 1728662.
DOI: 10.1136/hrt.79.4.331.
[Genetic causes of hypertrophic cardiomyopathy].
Vosberg H
Med Klin (Munich). 1998; 93(4):252-9.
PMID: 9594535
DOI: 10.1007/BF03044801.
Sudden death from cardiovascular disease in young athletes: fact or fiction?.
Sharma S, Whyte G, McKenna W
Br J Sports Med. 1998; 31(4):269-76.
PMID: 9429003
PMC: 1332559.
DOI: 10.1136/bjsm.31.4.269.
Altered patterns of cardiac intercellular junction distribution in hypertrophic cardiomyopathy.
Sepp R, Severs N, Gourdie R
Heart. 1996; 76(5):412-7.
PMID: 8944586
PMC: 484572.
DOI: 10.1136/hrt.76.5.412.
Prognosis of hypertrophic cardiomyopathy: assessment by 123I-BMIPP (beta-methyl-p-(123I)iodophenyl pentadecanoic acid) myocardial single photon emission computed tomography.
Nishimura T, Nagata S, Uehara T, Morozumi T, Ishida Y, Nakata T
Ann Nucl Med. 1996; 10(1):71-8.
PMID: 8814730
DOI: 10.1007/BF03165056.
The athlete's heart: is big beautiful?.
Shephard R
Br J Sports Med. 1996; 30(1):5-10.
PMID: 8665119
PMC: 1332256.
DOI: 10.1136/bjsm.30.1.5.
Screening for hypertrophic cardiomyopathy.
McLatchie G, Pedoe D, McKenna W, Butler C, Hillis W, Davies G
BMJ. 1993; 306(6881):860.
PMID: 8490401
PMC: 1677278.
DOI: 10.1136/bmj.306.6881.860.
Autonomic function in hypertrophic cardiomyopathy.
Gilligan D, Chan W, Sbarouni E, Nihoyannopoulos P, Oakley C
Br Heart J. 1993; 69(6):525-9.
PMID: 8343320
PMC: 1025165.
DOI: 10.1136/hrt.69.6.525.
